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ABSTRACT The number of invasive infections caused by Candida species is increas-
ing worldwide. The incidence of candidiasis cases caused by non-albicans Candida
species, such as Candida parapsilosis, is also increasing, and non-albicans Candida
species are currently responsible for more invasive infections than C. albicans. Addi-
tionally, while the development of azole resistance during invasive disease with C.
albicans remains uncommon, azole-resistant C. parapsilosis strains are frequently iso-
lated in the hospital setting. In this study, we applied direct selection to generate
azole-adapted and azole-evolved C. parapsilosis strains in order to examine the effect
of azole resistance development on fungal viability and pathogenesis progression.
Depending on the drug applied, the different evolved strains developed distinct
cross-resistance patterns: the fluconazole-evolved (FLUEVO) and voriconazole-evolved
(VOREVO) strains gained resistance to fluconazole and voriconazole only, while po-
saconazole evolution resulted in cross-resistance to all azoles and the posaconazole-
evolved (POSEVO) strains showed higher echinocandin MIC values than the FLUEVO
and VOREVO strains. Whole-genome sequencing results identified the development
of different resistance mechanisms in the evolved strains: the FLUEVO and VOREVO
strains harbored amino acid substitutions in Mrr1p (A808T and N394Y, respectively),
and the POSEVO strain harbored an amino acid change in Erg3p (D14Y). By revealing
increased efflux pump activity in both the FLUEVO and the VOREVO strains, along
with the altered sterol composition of the POSEVO strain, we now highlight the im-
pact of the above-mentioned amino acid changes in C. parapsilosis azole resistance
development. We further revealed that the virulence of this species was only slightly
or partially affected by fluconazole and voriconazole adaptation, while it significantly
decreased after posaconazole adaptation. Our results suggest that triazole adapta-
tion can result in azole cross-resistance and that this process may also result in viru-
lence alterations in C. parapsilosis, depending on the applied drug.
IMPORTANCE Candida parapsilosis causes life-threatening fungal infections. In the
last 2 decades, the increasing number of azole-resistant C. parapsilosis clinical iso-
lates has been attributable to the overuse and misuse of fluconazole, the first-line
antifungal agent most commonly used in several countries. To date, the range of
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applicable antifungal drugs is limited. As a consequence, it is essential to understand
the possible mechanisms of antifungal resistance development and their effect on
virulence in order to optimize antifungal treatment strategies in the clinical setting.
Our results revealed that the prolonged exposure to azoles resulted not only in
azole resistance but also in cross-resistance development. Our data further indicate
that resistance development may occur through different mechanisms that can also
alter the virulence of C. parapsilosis. These results highlight the consequences of
prolonged drug usage and suggest the need for developing alternative antifungal
treatment strategies in clinical practice.
KEYWORDS Candida, antifungal resistance, triazole, virulence
The number of invasive fungal infections is increasing worldwide (1), and Candidaspecies are the most common mycological cause of bloodstream infections (2).
Candida albicans remains the leading cause of invasive disease; however, the number
of infections caused by other Candida species, such as C. parapsilosis, C. glabrata, C.
tropicalis, and C. krusei, has increased markedly in the last 3 decades (2–5). Currently,
echinocandins are recommended as the first-line antifungal agents for the treatment of
systemic candidiasis (6–8), although triazoles, especially fluconazole, are commonly
utilized when the infecting species is susceptible to these agents. Although the majority
of C. parapsilosis clinical isolates are susceptible to azole antifungals, they have the
highest in vitro MIC values for echinocandins compared to other Candida species (7).
Despite the concern over high echinocandin MIC values in vitro, patients with C.
parapsilosis infection generally respond well to echinocandin treatment (9). In a previ-
ous study, we revealed how this paradoxical phenomenon can be explained: acquired
echinocandin resistance leads to attenuated virulence in vivo, possibly due to a fitness
cost (10). Interestingly, while C. albicans clinical isolates are rarely resistant to azole
derivatives, azole-resistant C. parapsilosis and C. glabrata strains are frequently isolated
from patients (11). Additionally, the rate of azole resistance among C. parapsilosis
isolates has increased over the past 2 decades (11–13). Prior to the introduction of
echinocandins in general practice, fluconazole was the first-line antifungal agent for
candidiasis treatment worldwide and is still prophylactically administered to certain
patients (14, 15). Azole cross-resistance (mostly between fluconazole and voricona-
zole) occurs in approximately two-thirds of fluconazole-resistant C. parapsilosis
isolates (16, 17).
Despite the emergence of azole-resistant C. parapsilosis clinical isolates, the molec-
ular mechanisms of azole resistance have been investigated mainly in C. albicans (a
species not typically associated with azole resistance during invasive disease) and in C.
glabrata, while only a limited number of studies have focused on C. parapsilosis (1, 18,
19). The development of resistance in Candida species has been described to be a result
of mutations in or the overexpression of ergosterol biosynthetic enzymes (e.g., Erg11)
or due to the overexpression of efflux pump-encoding genes (MDR1 and CDR1) as a
consequence of mutations in their corresponding transcription regulatory factors
(MRR1 and TAC1, respectively) (19, 20). However, species-specific investigations are
required, as certain mechanisms are not globally effective across the genus. In C.
albicans, the Upc2 transcription factor is responsible for ERG11 overexpression. In
contrast, this transcription factor does not possess the same role in C. parapsilosis, but,
rather, it is required for the overexpression of other ergosterol biosynthesis genes (19,
20). Similarly, previous studies have shown that while MDR1 and CDR1 overexpression
is important in terms of acquiring azole resistance in C. albicans, MDR1 and CDR1 play
a minor role in resistance development in C. parapsilosis (18, 21). Based on this
information, we aimed to investigate the specific adaptation mechanisms of C. parap-
silosis in response to long-term exposure to triazoles and the impact of the acquired
resistance on virulence in vivo.
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Azole-evolved C. parapsilosis strains developed altered susceptibility to differ-
ent antifungals, depending on the drug used for microevolution. Prior to the
microevolution process, the MIC values of fluconazole (FLU; 1 g/ml), voriconazole
(VOR; 0.031 g/ml), and posaconazole (POS; 0.031 g/ml) for the C. parapsilosis CLIB
214 strain were determined (Table 1). Next, we generated the adapted (ADP) strains by
incubating CLIB 214 cells in the presence of increasing amounts of one of the three
different antifungal drugs. Following direct selection, the evolved (EVO) strains were
derived from the adapted strains by repeated culturing in yeast extract-peptone-
dextrose (YPD) without the previously used antifungal following a scheme that we
previously described (10) and that is shown in Fig. 1.
The susceptibilities of the generated triazole-adapted and -evolved strains to am-
photericin B (AMP), azoles (FLU, VOR, POS, itraconazole [ITR]), and echinocandins
(caspofungin [CAS], anidulafungin [AND], micafungin [MICA]) were tested. Adapted
(ADP) strains were defined as cell populations grown in the presence of the maximal
concentration of a specific azole used during the microevolution process. Evolved (EVO)
strains were derived from ADP strains following their serial cultivation 10 times in YPD
without antifungals. Most of the adapted strains showed MIC values similar to those for
their corresponding evolved strains, except for the POSADP and POSEVO strains, as the
MICs of POS and ITR were much higher for the POSEVO strain than for the POSADP strain
(Table 1). The MIC values of AMP for all adapted and evolved strains increased 2- to
TABLE 1 MIC values of Candida parapsilosis parental, adapted, and evolved strains
Strain
MIC (g/ml)
AMP FLU VOR POS ITR CAS AND MICA
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
CLIB 214 0.5 0.25 1 1 0.031 0.031 0.031 0.031 0.063 0.063 1 1 1 2 1 2
FLUADP 1 1 128 128 2 2 0.031 0.031 0.125 0.25 1 1 1 1 0.5 2
FLUEVO 1 2 128 128 2 2 0.031 0.031 0.25 0.25 1 1 1 1 0.5 2
VORADP 0.5 0.5 256 256 8 8 0.031 0.031 0.25 0.25 0.5 0.5 1 1 0.5 1
VOREVO 1 2 256 256 8 8 0.031 0.031 0.25 0.25 1 1 1 1 0.5 1
POSADP 0.5 1 256 256 32 32 1 2 4 4 2 2 2 2 4 4
POSEVO 1 1 256 256 32 32 32 32 32 32 2 4 4 4 4 8
FIG 1 Process for the generation of triazole-adapted (ADP) and -evolved (EVO) strains.
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3-fold compared to those for the parental C. parapsilosis strain. There were slight
decreases in the echinocandin MIC values for the FLUADP, FLUEVO, VORADP, and VOREVO
strains (Fig. 2A, B, D, and E). However, the POSADP and POSEVO strains showed 2- to
4-fold increases in the MICs of the echinocandins (Fig. 2C and F). All azole-ADP and
-EVO strains developed resistance to FLU. Notably, the VORADP, VOREVO, POSADP, and
POSEVO strains all possessed higher MIC values (256 g/ml for fluconazole) than the
FLUADP or FLUEVO strains (Fig. 2A to F). All generated strains gained resistance to VOR,
with increasing MICs being seen for the FLUADP/FLUEVO strains (2 g/ml) and then the
VORADP/VOREVO strains (8 g/ml) and the POSADP and POSEVO strains (32 g/ml), for
which the values were the highest (Table 1; Fig. 2). The adapted and evolved strains
generated using FLU or VOR did not display cross-resistance to POS. In the case of ITR,
the FLUADP, FLUEVO, VORADP, and VOREVO strains displayed 2-fold increases in MIC
values (0.25 g/ml), and the POSADP and POSEVO strains developed resistance to this
antifungal drug (MICs, 4 g/ml and 32 g/ml, respectively).
Azole microevolution leads to altered stress tolerance. We compared the abiotic
stress tolerance of the evolved (EVO) strains to that of the CLIB 214 parental strain on
solid agar plates with a spot assay. On YPD plates, no differences in growth between
the EVO strains and the parental strain were detected (data not shown). In the presence
of glycerol, NaCl, and sorbitol, we detected slight or moderate growth defects at 30°C
for the VOREVO and POSEVO strains. Attenuated growth was more pronounced at 37°C
than at 30°C. Additionally, the FLUEVO strain showed slight growth defects at 37°C in the
presence of osmotic stressors.
Interestingly, the FLUEVO and VOREVO strains were able to surpass the parental CLIB
214 strain in growth in the presence of caffeine at both 30 and 37°C. In contrast, the
POSEVO strain showed a strong growth defect or no growth at all on caffeine-containing
plates. The growth of the VOREVO and POSEVO strains slightly and moderately de-
creased, respectively, in the presence of 50-g/ml calcofluor white (CW) at both 30°C
and 37°C. CW at 75 g/ml caused a strong growth defect in all triazole-evolved strains,
FIG 2 Spider web diagram representation of the changes in the antifungal susceptibilities of the C. parapsilosis (C. p.) FLUEVO (A, D), VOREVO (B, E), and POSEVO
(C, F) strains after 24 h (A to C) and 48 h (D to F).
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and the growth defect was the most vigorous in the presence of 100-g/ml CW in the
case of VOREVO at 37°C and POSEVO at both temperatures, where no growth was
detectable. In the presence of Congo red (CR), none of the strains, including the
parental C. parapsilosis CLIB 214 strain, were able to grow at 37°C (Fig. 3). Utilization of
10- and 25-g/ml CR caused only a slight decrease in growth in the case of the VOREVO
and POSEVO strains; however, higher concentrations of CR (50 g/ml, 75 g/ml) resulted
in a strong growth defect in all triazole-evolved strains.
Similarly, the membrane-perturbing compound sodium dodecyl sulfate (SDS) also
caused the complete arrest of the growth of all strains at 37°C. Interestingly, the FLUEVO
strain showed improved growth compared to that of the CLIB 214 parental strain, while
the VOREVO and POSEVO strains were also unable to grow at 30°C (Fig. 3).
Whole-genome sequencing (WGS) reveals different potential resistance mech-
anisms in the triazole-evolved strains. To ascertain a potential mechanism of triazole
resistance, we compared the genomes of the FLUEVO, VOREVO, and POSEVO strains to the
genome of the parental strain. All point mutations are listed in Data Set S1 in the
supplemental material. We detected 136, 144, and 142 nonsynonymous mutations in
121, 127, and 128 open reading frames (ORFs) in the genomes of the FLUEVO, VOREVO,
and POSEVO strains, respectively, when their sequences were compared to the sequence
of the parental C. parapsilosis CLIB 214 strain. Among these, 101 genes harbored at least
1 single nucleotide polymorphism (SNP) in all of the evolved strains. Inspection of the
functional annotation of the genes harboring the highest values of SNPs per kilobase
pair in all the experiments did not reveal any clear candidate related to the acquisition
of resistance. Therefore, we focused on genes that harbored mutations in both the
FLUEVO and VOREVO strains simultaneously or genes that were mutated only in the POS-
EVO strain and that according to their function may be directly responsible for the
acquisition of resistance. The mutations that met these criteria are highlighted in
Table 2. The FLUEVO and VOREVO strains harbored point mutations in the CPAR2_807270
region (C. albicans orthologue, MRR1, the transcriptional activator of MDR1) at contig
positions 1679479 and 1678237, causing the A808T and N394Y amino acid changes,
respectively. These two strains also had the same nonsynonymous mutation in the
FIG 3 Growth of the triazole-evolved strains in the presence of abiotic stressors compared to the growth of the C.
parapsilosis CLIB 214 parental strain. Asterisks indicate conditions under which the C. parapsilosis CLIB 214 parental strain
was unable to grow.
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CPAR2_100280 gene at contig position 45253, resulting in the F4L amino acid substi-
tution. The POSEVO strain harbored an SNP in the gene CPAR2_105550 potentially
responsible for azole and echinocandin resistance. These SNPs occurred at contig
position 1207930, leading to the D14Y amino acid change. CPAR2_105550 is a putative
gene orthologous to C. albicans ERG3, which participates in ergosterol biosynthesis and
which encodes a C-5 sterol desaturase.
The FLUEVO and VOREVO strains show elevated efflux pump activity. We next
examined the efflux pump activity and the MDR1 expression of the C. parapsilosis
azole-evolved strains. Staining with the acetoxymethyl (AM) ester derivative of calcein
(calcein-AM) is regularly used to determine efflux pump activity in yeasts (22). During
calcein-AM staining, the intracellular esterases cleave the AM group, which leads to the
inability of calcein to permeate the membrane, which results in its accumulation within
a cell, producing a strong intracellular fluorescent signal. If the efflux pump activity is
elevated within the host cell due to, e.g., the upregulation of the Mdr1 and Cdr1
proteins, calcein is transported into the extracellular space, and consequently, the
intracellular fluorescent signal weakens. We found that the fluorescent signal de-
creased in the FLUEVO and VOREVO strains compared to that in the parental CLIB 214 C.
parapsilosis strain, suggesting an increase in efflux activity in these strains, which could
be responsible for FLU and VOR cross-resistance development (Fig. 4A). Interestingly,
efflux pump activity decreased in the POSEVO strain compared to the parental strain
(Fig. 4A). To support the findings of the calcein-AM staining, we compared the
expression of MDR1, CPAR2_405280, and CDR1 (CPAR2_405290) in the FLUEVO, VOREVO,
and POSEVO strains to that in the parental C. parapsilosis strain. The expression levels in
the azole-evolved strains were normalized to the expression levels measured in the C.
parapsilosis CLIB 214 parental strain. We found that all three genes examined
(CPAR2_405280, CDR1, and MDR1) were expressed at a higher level in the FLUEVO and
VOREVO strains than in the C. parapsilosis CLIB 214 strain. In accordance with the
calcein-AM staining results, these genes were downregulated in the POSEVO strain. We
observed the highest MDR1 expression levels in the FLUEVO and VOREVO strains (5- and
13-fold increases, respectively), while MDR1 expression was 1.58 times lower in the
POSEVO strain than in the C. parapsilosis CLIB 214 strain (Fig. 4B). CPAR2_405280 and
CDR1 expression also increased, although to a lower extent in the FLUEVO and VOREVO
strains than in the parental strain: 1.7- and 2.49-fold increases, respectively, were
detected in the FLUEVO strain than in the parental strain, and 1.54- and 2.05-fold
increases, respectively, were observed in the VOREVO strain than in the parental strain.
In contrast, CPAR2_405280 and CDR1 expression levels decreased 2.44 and 1.36 times,
respectively, in the POSEVO strain compared to the C. parapsilosis CLIB 214 strain (Fig. 4C
and D).
Posaconazole evolution leads to an altered sterol composition possibly due to
an ERG3 loss-of-function mutation. For the validation of an ERG3 loss-of-function
mutation, we examined the sterol content of C. parapsilosis CLIB 214 parental and
azole-evolved strains in the presence and absence of the appropriate azole. The relative
sterol composition of each strain was determined by liquid chromatography– high-
resolution mass spectrometry (LC-HRMS) and gas chromatography-mass spectrometry,
and the raw data are available in Data Set S2. Figure 5A depicts a schematic of the
TABLE 2 Amino acid substitutions in genes potentially responsible for resistance in C. parapsilosis triazole-evolved strains (FLUEVO,
VOREVO, POSEVO) compared to the parental CLIB 214 strain
Gene Strain(s) C. albicans orthologue Orthologue function Amino acid substitution
CPAR2_807270 FLUEVO, VOREVO MRR1 Activator of Mdr1 efflux
pump
A808T (for FLUEVO), N394Y (for VOREVO)
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ergosterol biosynthesis pathway, including the main detectable components derived
from our sterol composition results. In the untreated parental C. parapsilosis CLIB 214
strain, the main sterol component was ergosterol (97.74%), while treatment with each
of the azoles reduced the ergosterol content to below 2%. Instead of ergosterol, the
most abundant sterol compounds were lanosterol (31.28 to 35.56%), 14-methyl (Me)-
fecosterol (23.36 to 27.04%), and 14-Me-ergosta-dien-diol (which is toxic; 20.02 to
23.54%). Additionally, we also identified two as yet uncharacterized sterol compounds
(US): US2 (2.57 to 6.37%) and US3 (10.74 to 12.7%) (Fig. 5B to D; Data Set S2). The
FLUEVO strain produced ergosterol in the presence (90.39%) or absence (93.45%) of FLU
(Fig. 5B; Data Set S2). The pattern of the sterol composition of C. parapsilosis VOREVO
azole-untreated cells showed similarities to that of untreated CLIB 214 cells and both
treated and untreated FLUEVO strains, as ergosterol was the major sterol component in
these samples (95%). In contrast to the FLU-treated FLUEVO strain, the VOR-treated
VOREVO strain contained a smaller amount of ergosterol (66.26%) and accumulated
more lanosterol (13.17%), 14-Me-ergosta-dien-diol (9.22%), and 14-Me-fecosterol
(4.43%) and a smaller amount of US2 (1.39%) and US3 (4.91%) (Fig. 5C; Data Set S2). In
the case of the POSEVO strain under both the POS-treated and the untreated circum-
stances, the sterol composition pattern was completely different from that of CLIB 214
or the FLUEVO and VOREVO strains. Ergosterol was detectable in infinitesimally small
amounts in the POSEVO strain in the presence or absence of POS. In the absence of POS,
the major sterol component was fecosterol/episterol/ergosta-dienol (92.34%, detected
all together). Furthermore, small amounts of another yet unidentified sterol (US1,
3.96%) and ergosta-enol (1.53%) were detected in the POSEVO strain (Fig. 5D; Data Set
S2). In the presence of POS, the POSEVO strain mainly produced 14-Me-fecosterol
FIG 4 Efflux activity of C. parapsilosis CLIB 214, FLUEVO, VOREVO, and POSEVO strains. (A) Efficiency of
calcein efflux from cells of the C. parapsilosis CLIB 214, FLUEVO, VOREVO, and POSEVO strains. (B to D)
Normalized expression profile of MDR1 (B), CPAR2_405280 (C), and CDR1 (D). *, P  0.05; **, P  0.01; ***,
P  0.001; ****, P  0.0001.
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(82.81%) and lanosterol (12.21%) (Fig. 5D; Data Set S2). These data about the POSEVO
strain suggest an ERG3 loss-of-function mutation (Fig. 5A).
Azole microevolution alters the in vivo virulence properties of evolved strains
in a mouse model. We next investigated the virulence of the triazole-evolved strains
in a mouse model of systemic candidiasis. The fungal burdens of the evolved strains in
the kidneys and/or brain were altered from those of the parental strain (Fig. 6), but
there were no significant changes in the numbers of CFU in the liver and spleen (data
not shown). Although adaptation to FLU did not affect kidney colonization, significant
decreases in the numbers of CFU recovered after VOREVO and POSEVO infection com-
pared to the numbers of CFU recovered after infection of this organ with the parental
strain were detected. Notably, the number of CFU recovered following infection with
the POSEVO strain was significantly lower even than the number of CFU recovered
following infection with the VOREVO strain (Fig. 6). Interestingly, the fungal burden in
FIG 5 Altered sterol composition of the C. parapsilosis (C. par) CLIB 214, FLUEVO, VOREVO, and POSEVO strains in the presence and absence of fluconazole,
voriconazole, or posaconazole. (A) Schematic of ergosterol biosynthesis (black arrows) and its alterations due to azole treatment (red arrows) and ERG3
loss-of-function mutations (blue arrows). Dashed lines represent the unclear origin of recently detected, yet unidentified sterols. (B to D) Sterol composition of
fluconazole-related (B), voriconazole-related (C), and posaconazole-related (D) samples.
FIG 6 Fungal burden of the brain and kidneys of BALB/c mice at 3 days postinfection. Data are for 12
mice from each group from 3 different experiments. Statistical analyses were performed by Mann-
Whitney tests. *, P  0.05; ****, P  0.0001; ns, not significant.
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the brain significantly increased after FLUEVO infection, while no difference was de-
tected in the case of VOREVO infection, and a significant decrease in the number of CFU
was observed after infection with the POSEVO strain relative to the number of CFU seen
after infection with the parental strain.
In comparing the virulences of the triazole-evolved strains to each other, we found
that the POSEVO strain showed the greatest virulence attenuation in both organs,
followed by the VOREVO strain in the kidneys and the FLUEVO strain, which showed no
virulence attenuation. When comparing the findings for the evolved strains to those for
the parental strain, we can conclude that POS evolution led to the highest cost of
virulence both in the kidneys and in the brain, while VOR evolution resulted in a loss
of virulence only in the kidneys and FLU evolution had either no effect or a gain-of-
virulence effect in both organs (Fig. 6).
DISCUSSION
In our previous study, we demonstrated the relationship between acquired echino-
candin (caspofungin, anidulafungin, micafungin) resistance and the virulence proper-
ties of C. parapsilosis. We found that the development of echinocandin resistance
attenuates the virulence of C. parapsilosis in vivo independently of the applied echi-
nocandin (10).
Here we aimed to explore the mechanisms of resistance to different triazoles (FLU,
VOR, POS) and the consequences of adaptation on stress tolerance and virulence
properties. First, we generated three independent triazole-evolved (FLUEVO, VOREVO,
POSEVO) strains by repeatedly passaging C. parapsilosis CLIB 214 cells in the presence of
increasing drug concentrations (Fig. 1). Previous studies showed that azole resistance
development may also lead to increased MIC values or even resistance to echinocan-
dins (23, 24). Our FLUEVO and VOREVO strains showed a similar resistance pattern, as
these two strains developed resistance to both FLU and VOR; however, the POS MIC did
not change and only a 1-fold increase or decrease in the MICs of the other antifungals
examined was observed. It is important to note that both the FLU and VOR MIC values
appeared to be significantly higher for the VOREVO strain than for the FLUEVO strain.
Despite the increasing number of FLU-VOR cross-resistant isolates (possibly due to
shared resistance mechanisms [25]), successful VOR treatments were also reported in
experimental and clinical cases of FLU-resistant Candida infection. In other cases, FLU
treatment was not successful (26, 27). This clinical observation could be an explanation
for the different FLU and VOR MIC values for the FLUEVO and VOREVO strains. The pattern
of the MIC values for the POSEVO strain differed significantly from the patterns for the
other two azole-evolved strains. VOR is a derivative of FLU, and cross-resistance
between these two related azoles is frequent. In contrast, POS is a derivative of
itraconazole, and cross-resistance with FLC or VOR is much less frequent (28). Thus,
structural relations between the different azoles may explain the pattern of MIC values
of the azole-evolved strains. The POSEVO strain possessed the highest MIC value for all
tested azoles. In contrast to the findings for the FLUEVO and VOREVO strains, the POSEVO
strain showed increased echinocandin MIC values. The patterns in the resistance of the
generated strains anticipated some of the differences in the resistance mechanisms of
the different evolved strains. In contrast to the results of the MIC distribution, the
POSEVO strain was the most susceptible to all osmotic, cell wall, and plasma membrane
stressors. Interestingly, the FLUEVO and the VOREVO strains were resistant to the cell wall
stressor caffeine.
Results from whole-genome sequencing produced insights into potential resistance
mechanisms responsible for the different MIC values. According to the sequencing
results, the resistance in our FLUEVO and VOREVO strains possibly developed due to two
different SNPs in the MRR1 gene, responsible for MDR1 transcription activation (21).
However, we did not find any nucleotide changes in TAC1, activating constitutive CDR1
expression (18). It is possible that the different levels of FLU and VOR resistance of the
FLUEVO and VOREVO strains were due to the distinct nature of the amino acid substi-
tutions (A808T and N394Y, respectively); however, there is no evidence in the literature
Drug-Dependent Impact on Virulence of C. parapsilosis
September/October 2020 Volume 5 Issue 5 e00821-20 msphere.asm.org 9
 on F























about the effect of alternative SNPs in MRR1. The POSEVO strain did not harbor any SNPs
in MRR1 or TAC1. Previous studies showed that MRR1 is not necessarily responsible for
increased MDR1 expression, as the disruption of MRR1 decreases only FLU MIC values
(18). However, the identified MRR1 mutations in the FLUEVO and VOREVO strains in this
study may suggest otherwise, as these strains showed significantly increased MIC
values for FLU and VOR, which was possibly due to elevated efflux pump activity.
Interestingly, in the FLUEVO and VOREVO strains, in addition to the elevated expression
of MDR1, the expression of CPAR2_405280 and CDR1 (potential ABC transporters) also
increased. These findings and those of Berkow et al. (18) suggest that in C. parapsilosis,
expression of the MDR1 and CDR genes is positively regulated via redundant transcrip-
tion circuits, which are less dependent on gain-of-function SNPs of transcription factors,
such as MRR1 or TAC1. Furthermore, the function of a redundant transcriptional system
may not be necessarily dependent on the presence of azoles, as we detected elevated
expression of MDR1 and CDR genes in untreated samples; however, MRR1 is clearly a
positive regulator of MDR1 expression. Regarding the efflux activity together with the
stress response to caffeine, we hypothesize that caffeine may also be a substrate of
efflux pumps, in contrast to the other stressors used in this study. Our results on the
MIC distribution together with the resistance mechanisms of the FLUEVO and VOREVO
strains are consistent with the findings in the literature, as POS is not a substrate of MSF
or ABC transporters (20, 25, 29). Therefore, during the generation of the POSEVO strain,
another path had to be involved in POS resistance development. According to the WGS
results, together with the sterol composition data (a lack of sterol compounds down-
stream of Erg3p and the accumulation of sterol compounds upstream of Erg3p), for the
POSEVO strain, we suggest that the mutation in ERG3 is responsible for a wide range of
azole resistance. It is consistent with the findings in the literature that the elevated
echinocandin MIC values are connected to ERG3 loss-of-function mutations, although
the exact molecular mechanism regarding how the loss or decrease of C-5 sterol
desaturase activity could lead to echinocandin resistance in C. parapsilosis is still unclear
(30). It may be hypothesized that the altered sterol content could lead to an elevated
stress response, leading to a compensation effect of echinocandins. The first part of this
hypothesis was confirmed, as we demonstrated the altered sterol composition of the
POSEVO strain. Additionally, the accumulated fecosterol/episterol/ergosta-dienol levels
in the POS-untreated POSEVO strain and 14-Me-fecosterol levels in the POS-treated
POSEVO samples highlight the loss-of-function characteristic of the ERG3 mutation in
this strain. The sterol composition of the FLUEVO and VOREVO strains treated with the
corresponding azole showed the effectiveness of VOR even in resistant isolates, as the
VOR-treated VOREVO strain produced less ergosterol and accumulated a higher portion
of 14-Me-ergosta-dien-diol than the untreated CLIB 214, FLU-untreated FLUEVO, and
FLU-treated FLUEVO strains. We detected three unidentified sterol components in
different strains under different conditions. We plan to elucidate the exact structure of
these compounds by nuclear magnetic resonance spectroscopy in collaboration with
analytical experts.
Interestingly, the in vivo virulence properties of the azole-evolved strains showed a
pattern reciprocal to that for the MIC values. For example, the FLUEVO strain was as
virulent as the parental CLIB 214 strain, despite having the lowest MIC values of azoles
compared to the other azole-evolved strains. Previous studies showed that FLU treat-
ment in Galleria mellonella larvae is ineffective against FLU-resistant C. parapsilosis
strains (31). This information, together with our results, indicates that adaptation to FLU
does not imply a virulence cost in C. parapsilosis, as in the case of echinocandin
adaptation (10). In C. glabrata PDR1 (CgPDR1), gain-of-function mutations not only lead
to elevated azole MICs but also enhance virulence, indicating that CgPDR1 possibly
regulates uncharacterized virulence factors (32). C. parapsilosis MRR1 (CpMRR1) regu-
lates MDR1, but we found elevated expression of CDR genes (CPAR2_405280, CDR1) in
strains bearing SNPs in MRR1; therefore, the possibility that MRR1 regulates the expres-
sion of other unidentified genes responsible for virulence in C. parapsilosis cannot be
excluded. This hypothesis must be confirmed by further experiments, as the virulence
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of the VOREVO strain was attenuated in the kidney but not in the brain of infected mice,
despite the shared resistance mechanism with the FLUEVO strain. This can be explained
by the distinct MRR1 mutation, MDR1 expression, and efflux pump activity or by the
uncharacterized changes in the transcriptome of the VOREVO strain. The virulence of the
POSEVO strain was attenuated the most, as the numbers of CFU were the lowest both
in the kidneys and in the brain of POSEVO-infected mice compared to those of the other
strains. The impaired virulence of POSEVO is possibly due to ERG3 inactivation, as in C.
albicans the lack of sterol Δ5,6-desaturase activity leads to decreased virulence (33, 34).
However, there is an example in C. albicans in which this resulted in a reduced but not
absent expression of ERG3, such that resistance to azoles occurred, but no changes in
virulence properties were detected (35).
In summary, the POSEVO strain was the least virulent, which was possibly due to its
high susceptibility to stressors. Stress tolerance and the virulence pattern were similar
in the case of the FLUEVO and VOREVO strains. This may have been due to the fact that
voriconazole is a derivative of fluconazole, as the corresponding strains showed similar
phenotypic changes. Based on the genome analysis results, the genes affected by SNPs
may be responsible for the differences between the POSEVO and the FLUEVO/VOREVO
strains, of which MRR1 and ERG3 are annotated in C. parapsilosis. Based on the Candida
Genome Database, none of the other CPAR2 genes have an orthologous gene that
could be related to antifungal resistance, the stress response, or virulence regulation.
Our results, together with the findings in the literature, highlight the necessity of
deeper investigations of antifungal resistance development in C. parapsilosis and other
species, as the outcome of different antifungal treatments may depend not only on the
effectiveness of administered antifungal drugs but also on the virulence cost effect that
could be impacted by resistance mechanisms (36).
MATERIALS AND METHODS
Generation of azole-evolved strains. Triazole-evolved strains were generated as described previ-
ously (10, 37), with minor modifications (Fig. 1). To determine the initial concentration of triazoles for the
microevolution process, we determined the MIC values of FLU, VOR, and POS for the parental C.
parapsilosis CLIB 214 strain (38). For microevolution, the initial concentration of each drug was half of the
MIC values determined for the parental strain: 0.5 g/ml, 0.0156 g/ml, and 0.0156 g/ml for FLU, VOR,
and POS, respectively.
Strains and culturing conditions. The strains utilized in this study are listed in Table 3. Before each
experiment, each C. parapsilosis strain was cultured in YPD broth at 30°C for 16 h and then 200-l
aliquots were inoculated into 5 ml fresh YPD liquid medium and incubated at 30°C for 16 h. The parental
C. parapsilosis CLIB 214 strain was maintained on YPD, while the FLUEVO, VOREVO, and POSEVO strains were
maintained on YPD agar plates supplemented with 64 g/ml, 8 g/ml, and 8 g/ml FLU, VOR, and POS,
respectively.
Antifungal susceptibility test. MIC values were determined according to the M27-A3 protocol (39),
and MIC values were defined by the M27-S4 supplementary document (40). MICs were measured in RPMI
1640 with MOPS (morpholinepropanesulfonic acid) with L-Gln but without NaHCO3 (catalog number
04-525F; Lonza) at 24 h and 48 h. The MIC values for the echinocandins were defined as the lowest
concentrations that resulted in at least 50% growth reduction. Amphotericin B (AMP; Sigma-Aldrich),
azoles (FLU, VOR, POS, and ITR; Sigma-Aldrich), and echinocandins (CAS [Sigma-Aldrich] and AND and
MICA [MedChem Express]) were utilized to test the susceptibilities of the C. parapsilosis strains.
Abiotic stress tolerance. The C. parapsilosis CLIB 214, FLUEVO, VOREVO, and POSEVO strains were
serially diluted, and 104, 103, 102, and 101 cells were transferred in 5 l to solid YPD plates adjusted to
pH 4, pH 5, pH 6, pH 7, or pH 8 (McIlvaine buffer) and to YPD plates without any supplements. For
comparing the growth abilities of the triazole-evolved strains to the growth ability of the parental CLIB
214 strain in the presence of osmotic and oxidative stressors as well as cell membrane- and cell
TABLE 3 C. parapsilosis strains used in this study
Strain Origin Reference or source
CLIB 214 Laboratory type strain 38
FLUADP CLIB 214 This work
VORADP CLIB 214 This work
POSADP CLIB 214 This work
FLUEVO FLUADP This work
VOREVO VORADP This work
POSEVO POSADP This work
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wall-perturbing agents, we plated the strains on YPD agar plates complemented with 8% (wt/vol), 10%
(wt/vol), or 12% (wt/vol) glycerol, 1 M or 1.5 M NaCl, or 1 M sorbitol (as osmotic stressors); with 0.05 mM
CdSO4 or 5 mM or 10 mM H2O2 (as oxidative stressors); with 12.5 mM, 15 mM, or 17.5 mM caffeine;
50-g/ml, 75-g/ml, or 100-g/ml calcofluor white, or 10-g/ml, 25-g/ml, 50-g/ml, or 75-g/ml
Congo red (as cell wall-perturbing agents); or with 0.02% (wt/vol), 0.04% (wt/vol), or 0.06% (wt/vol) SDS
(as a membrane-perturbing agent). The plates were incubated at 30°C and 37°C for 48 h. The growth
scores of the evolved (EVO) strains were determined and compared to those of the parental strain. All
experiments were repeated two times. We defined the defect scores as described previously (10): a score
of 1 was a strong defect, in which the growth of the given evolved strain spot, which was three times
more concentrated than that of the most diluted CLIB 214 spot in which growth appeared, was reduced
(smaller colonies or lower colony numbers); a score of 2 was a medium defect, in which similar numbers
of CFU appeared in the given evolved strain spot, which was two times more concentrated than the most
diluted CLIB 214 spot in which growth appeared; and a score of 3 was a slight defect, in which the growth
in the given evolved strain spot at one time the concentration of the most diluted CLIB 214 spot in which
growth appeared was reduced or colonies smaller than the parental strain’s colonies were present.
In vivo infection of mice and determination of fungal burden. For determining fungal burdens,
10- to 12-week-old female BALB/c mice (catalog number XVI./2015; BRC, Szeged, Hungary) were injected
via the lateral tail vein with 2  107 yeast cells in 100 l phosphate-buffered saline (PBS) (n  10 mice per
C. parapsilosis strain). At 3 days postinfection, the animals were euthanized and the liver, spleen, kidneys,
and brain were collected, weighed, and homogenized with an Ultra-Turrax T25 homogenizer (Sigma).
Organ homogenates were plated onto YPD agar plates supplemented with 1% penicillin-streptomycin,
and the numbers of CFU were counted after 48 h of incubation at 30°C.
Ethics statement. Animal experiments were performed according to Hungarian national animal
ethics guidelines (guideline 1998, XXVIII; 40/2013) and European animal ethics guidelines (guideline
2010/63/EU). The procedures were licensed by the Animal Experimentation and Ethics Committee of the
Biological Research Centre of the Hungarian Academy of Sciences and the Hungarian National Animal
Experimentation and Ethics Board (clearance number XVI./03521/2011), with the University of Szeged
granting permission XII./00455/2011 and XVI./3646/2016 to work with mice.
Genome sequencing. Libraries for whole-genome DNA sequencing were prepared with a Nextera XT
DNA library preparation kit (Illumina) with Nextera XT index kit adapters following the manufacturer’s
protocol for sequencing runs of 2  250 cycles. The sequencing libraries were validated and quanti-
tated with an Agilent 2100 Bioanalyzer capillary electrophoresis instrument using an Agilent DNA 1000
kit. After pooling and denaturing, the libraries were sequenced with an Illumina MiSeq sequencer using
a MiSeq reagent kit (version 3-600). Th paired-end read length was 2  300 bp, and the final average per
base sequencing depth ranged from 46 to 130 times.
Genome analysis of C. parapsilosis strains. Paired-end fastq reads files were first trimmed using the
Trimmomatic tool (version 0.36) (41). The parameters employed were as follows: we removed leading
and trailing nucleotides with a quality below 10 (the LEADING and TRAILING parameters, respectively),
we used 4-nucleotide sliding windows and cut when the average quality per nucleotide in a window was
below 15 (the SLIDINGWINDOW parameter), and we dropped any reads that were less than 40
nucleotides after this trimming (the MINLEN parameter). Then, we mapped the trimmed reads with the
bwa-mem tool from BWA (version 0.7.12-r1039) software (42). The reference genome against which the
reads were mapped was the CDC317 strain fasta file obtained in April 2018 from the Candida Genome
Database (43). We generated BAM files from this output using the SortSam and MarkDuplicates
commands from the Picard (version 2.15.0) set of tools (http://broadinstitute.github.io/picard/). Finally,
we called variants from these reads using the Freebayes (version 1.1.0-9-g09d4ecf) program (44) to jointly
genotype all the strains involved. We filtered the SNPs using the vcffilter tool from the vcflib library (E.
Garrison, https://github.com/vcflib/vcflib). We removed any SNPs for which the mean mapping quality
(MQM) value was below 30, the QUAL (quality) value was below 20 (indicating a probability of a false
variant call greater than 0.01), and/or the read depth (DP) was below 30.
Analysis of calcein efflux of C. parapsilosis strains by flow cytometry. C. parapsilosis CLIB 214 and
the evolved strains were washed with Hanks balanced salt solution (HBSS; Lonza) three times, and then
109 cells of each strain were coincubated with 20 g/ml calcein-AM (Merck) in 300 l HBSS for 90 min
with gentle shaking at 30°C. Next, the cells were washed with HBSS three times and incubated in HBSS
supplemented with 1% glucose without calcein-AM for 90 min.
After the second 90-min incubation, the cells were washed three times with PBS without glucose and
were resuspended in 200 l PBS. Unstained cells were used as negative controls. The fluorescence
intensity of 104 cells of each strain was examined using an Amnis Flow Sight imaging flow cytometer with
a 488-nm laser (Amnis, Merck Millipore, Billerica, MA, USA). Data analysis was performed using image
data exploration and analysis software (IDEAS; Amnis, Merck Millipore, Billerica, MA, USA).
RNA extraction and qRT-PCR analysis of MDR1 expression. The C. parapsilosis CLIB 214, FLUEVO,
VOREVO, and POSEVO strains were cultured for 16 h at 30°C. Following centrifugation, 107 cells were
inoculated into 1 ml liquid YPD medium with 1% penicillin-streptomycin and incubated at 30°C for 3 h.
Next, the cells were collected and washed three times with PBS and then stored in liquid nitrogen for
later RNA extractions.
RNA extraction was performed using a RiboPure RNA purification kit, yeast (catalog number AM1926;
Ambion), according to the manufacturer’s recommendations. An additional DNase treatment step was
applied using an RNase-free DNase set (catalog number 79254; Qiagen). DNA contamination in purified
RNA samples was checked by quantitative real-time PCR (qRT-PCR). cDNA synthesis was performed from
RNA samples containing 500 ng RNA, using a RevertAid first-strand cDNA synthesis kit (catalog number
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K1622; Thermo Scientific). The qRT-PCR experiments were performed in triplicate, using MDR1-,
CPAR2_405280-, or CPAR2_405290-specific and TUB4-specific primers (TUB4 was the housekeeping gene
that served as an internal control) (Table 4) and a Maxima SYBR green/fluorescein quantitative PCR
master mix (catalog number K0243; Thermo Scientific) in a CFX96 real-time system on a C1000 thermal
cycler (Bio-Rad). Expression is shown as the fold change, established by ΔΔCT threshold cycle (CT) analysis.
Determining the sterol composition by LC-HRMS. (i) Sample preparation. Cell suspensions were
adjusted to 107 cells/ml. Azole-exposed samples were treated with 32-g/ml FLU, 8-g/ml VOR, or
8-g/ml POS. All samples were incubated at 30°C in liquid YPD medium for 24 h. Sample preparation was
performed as described by Varga et al., with some modifications (45). The freeze-dried samples (10 mg)
were saponified with 2 ml of 10% KOH in methanol at 80°C for 90 min. Water (500 l) and n-hexane (1 ml)
were added to the cooled samples, and the mixtures were vortexed for 0.5 min. After separation of the
phases, the n-hexane phase was transferred to a 2-ml vial and evaporated to dryness under N2. The
extraction with n-hexane was repeated twice. The dried extracts were dissolved in 300 l of methanol
and filtered through a 0.2-m-pore-size polytetrafluoroethylene membrane filter.
(ii) LC-HRMS. Chromatographic analysis of the samples was performed using a DionexUltimate 3000
ultra-high-performance liquid chromatography system equipped with a membrane degasser, a binary
pump, a standard autosampler, a thermostated column compartment, and a variable-wavelength
detector. The sterols were separated on a Gemini-NX C18 column (particle size, 3 m; 150 by 2 mm;
Phenomenex) equipped with a Gemini-NX C18 guard column (particle size, 5 m; 4 by 2 mm) with a
gradient of methanol-water (9/1, vol/vol) as mobile phase A and methanol as mobile phase B at 40°C. The
gradient elution was performed as follows: 0.0 min, 0% mobile phase B; 1.0 min, 0% mobile phase B;
5.0 min, 100% mobile phase B; 10.0 min, 100% mobile phase B; 10.5 min, 0% mobile phase B; 15.0 min,
0% mobile phase B. The flow rate was set to 0.4 ml/min. The injection volume was 5 l.
Mass analyses were carried out with a Q Exactive Plus hybrid quadrupole-Orbitrap mass spectrometer
equipped with an atmospheric pressure chemical ionization (APCI) ion source operating in the positive
ion mode. The temperature of the ion transfer capillary, the spray voltage, the sheath gas flow rate, and
the auxiliary gas flow rate were set to 350°C, 4.5 kV, 40 arbitrary units, and 10 arbitrary units, respectively.
All data were acquired using the full-scan/ddMS2 (full-scan/data-dependent tandem mass spectrometry)
mode. All full-scan data were acquired over an m/z range of 300 to 500 at a resolution of 70,000 FWHM
(full width at half maximum) with a 1.0  106 automatic gain control (AGC) target and 100 ms of
maximum ion injection time. The acquired data were processed using the Xcalibur (version 2.2.1) and
Trace Finder (version 3.3) programs (Thermo Fisher Scientific). The identification of the compounds was
based on high-resolution accurate mass analysis when reference standards were not available.
Statistical analysis. Statistical analysis was performed and statistical significance was determined
using GraphPad Prism (version 6.01) software. Nonparametric Mann-Whitney tests were applied. Results
are presented as the mean and standard deviation. Differences between the groups examined were
considered statistically significant when the P value was 0.05.
Accession number(s). Raw sequencing data for the wild-type CLIB 214 strain are available under
BioProject accession number PRJNA493002 with SRA accession number SRR7898457. Sequence data for
the evolved strains are available under BioProject accession number PRJNA649004, and the SRA
accession numbers for the strains are as follows: SRR12333224 (FLUEVO), SRR12333223 (VOREVO), and
SRR12333222 (POSEVO).
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
DATA SET S1, XLS file, 0.3 MB.
DATA SET S2, XLSX file, 0.02 MB.
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